HC Wainwright Reaffirms Buy Rating for Merus (NASDAQ:MRUS)

Merus (NASDAQ:MRUS)‘s stock had its “buy” rating restated by stock analysts at HC Wainwright in a research note issued to investors on Monday,Benzinga reports. They currently have a $85.00 price target on the biotechnology company’s stock. HC Wainwright’s price objective points to a potential upside of 83.94% from the stock’s previous close.

MRUS has been the topic of a number of other reports. UBS Group began coverage on shares of Merus in a research report on Thursday, October 24th. They set a “buy” rating and a $72.00 target price on the stock. Guggenheim increased their price target on Merus from $93.00 to $111.00 and gave the company a “buy” rating in a research note on Tuesday, October 1st. Needham & Company LLC restated a “buy” rating and issued a $85.00 price target on shares of Merus in a research report on Wednesday, November 20th. Finally, The Goldman Sachs Group initiated coverage on shares of Merus in a research report on Thursday, November 21st. They issued a “buy” rating and a $73.00 target price on the stock. One research analyst has rated the stock with a sell rating, twelve have given a buy rating and two have assigned a strong buy rating to the company. According to MarketBeat, Merus has an average rating of “Buy” and an average price target of $85.27.

Merus Stock Down 4.8 %

Shares of MRUS stock opened at $46.21 on Monday. The company has a market capitalization of $3.16 billion, a P/E ratio of -11.70 and a beta of 1.07. Merus has a 12-month low of $22.27 and a 12-month high of $61.61. The firm has a 50-day moving average price of $49.90 and a 200 day moving average price of $51.89.

Merus (NASDAQ:MRUS) last announced its earnings results on Thursday, October 31st. The biotechnology company reported ($0.95) EPS for the quarter, missing the consensus estimate of ($0.90) by ($0.05). Merus had a negative return on equity of 38.89% and a negative net margin of 680.61%. The business had revenue of $11.77 million during the quarter, compared to analyst estimates of $9.11 million. As a group, research analysts expect that Merus will post -3.89 earnings per share for the current year.

Institutional Trading of Merus

Several large investors have recently bought and sold shares of the stock. nVerses Capital LLC raised its position in shares of Merus by 750.0% during the 3rd quarter. nVerses Capital LLC now owns 1,700 shares of the biotechnology company’s stock worth $85,000 after purchasing an additional 1,500 shares during the last quarter. US Bancorp DE purchased a new position in shares of Merus in the 3rd quarter valued at about $103,000. Mirae Asset Global Investments Co. Ltd. boosted its position in shares of Merus by 24.7% during the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,467 shares of the biotechnology company’s stock worth $118,000 after acquiring an additional 489 shares in the last quarter. Farallon Capital Management LLC purchased a new position in shares of Merus during the second quarter worth about $237,000. Finally, ProShare Advisors LLC purchased a new position in shares of Merus during the second quarter worth about $242,000. Hedge funds and other institutional investors own 96.14% of the company’s stock.

Merus Company Profile

Merus N.V., a clinical-stage immuno-oncology company, engages in the development of antibody therapeutics in the Netherlands. Its bispecific antibody candidate pipeline includes Zenocutuzumab (MCLA-128), which is in a phase 2 clinical trials for the treatment of patients with metastatic breast cancer and castration-resistant prostate cancer, as well as in Phase 1/2 clinical trials for the treatment of solid tumors that harbor Neuregulin 1.